WoondongJeongMD

Oncology • Tomball, TX

Hematologic Oncology

Millennium oncology

Join to view full profile

Dr. Jeong is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Jeong's full profile

Already have an account?

Office
506 Graham Dr
Ste 120
Tomball, TX 77375
Phone+1 281-516-0236

Fax+1 281-719-5930

Education & Training

Westchester Medical CenterFellowship, Hematology and Medical Oncology, 2003 - 2006
Westchester Medical CenterResidency, Internal Medicine, 2000 - 2003
Catholic University Medical CollegeClass of 1998

Certifications & Licensure

TX State Medical License 2014 - 2025
NY State Medical License 2010 - 2015
NJ State Medical License 2010 - 2013
ME State Medical License Active through 2011
American Board of Internal Medicine Medical Oncology

Clinical Trials

S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer Start of enrollment: 2015 May 07
Active, not recruiting
Phase 2, Phase 3
A Safety and Efficacy Study of INC280 Alone, and in Combination With Erlotinib, Compared to Chemotherapy, in Advanced/Metastatic Non-small Cell Lung Cancer Patients With EGFR Mutation and cMET Amplification Start of enrollment: 2015 Sep 23
Terminated
Phase 1
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches Start of enrollment: 2014 Nov 01
Completed
Phase 2
Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Sep 01
Completed
Phase 2, Phase 3
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Start of enrollment: 2015 Dec 29
Active, not recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

932 citations
Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical update
Naoko Takebe, Lucio Miele, Pamela Jo Harris, Woondong Jeong, Hideaki Bando
Nature Reviews. Clinical Oncology. 2015-08-01
115 citations
Pilot trial of EZN-2968, an antisense oligonucleotide inhibitor of hypoxia-inducible factor-1 alpha (HIF-1α), in patients with refractory solid tumors
Woondong Jeong, Annamaria Rapisarda, Sook Ryun Park, Robert J. Kinders, Alice P. Chen
Cancer Chemotherapy and Pharmacology. 2014-02-01
88 citations
Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor α-targeting antibody-drug conjugate, in patients with solid tumors.
Kathleen N. Moore, Hossein Borghaei, David M. O'Malley, Woondong Jeong, Shelly Seward
Cancer. 2017-08-15